Welcome Future Presenters of the 2022 ASCP Annual Meeting.
The Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) will be held at the Fairmont Scottsdale Princess, May 31 – June 03, 2022 . The Program Committee welcomes submissions from the U.S. as well as international proposals. This year, the Program Committee strongly encourages the composition of panels and workshops that include women, under-represented minorities, and early career researchers, investigators, and clinicians.
The theme of this year’s meeting is “Reassessing Research and Clinical Practice in the Peri-Pandemic Era”.
All presenters are required to complete an electronic disclosure as part of the submission process for all submission types.
Poster Presentation – Poster board presentation in a general session. View submission instructions for Posters Presentations.
Individual Research Report – Selected by the Program Committee, these are 10 minute oral presentation with 5 minutes Q&A from the audience. View submission instructions for Individual Research Reports.
Panel Sessions – Have a Chair, a minimum of 3 Speakers but no more than 4 speakers, and a discussant. A co-chair is optional. Panel sessions are 1.5 hours in length. View submission instructions for Panel Sessions.
Workshop Sessions – Integrative session with a chair and no more than 8 participants. A discussant and co-chair is optional. Workshop sessions are 2 hours in length. View submission instructions for Workshop Sessions.
Pharmaceutical Pipeline Presentations – A Pharmaceutical Pipeline report will be a 10 minute presentation and will also have the opportunity to present their research as a poster presentation. A Pharmaceutical Pipeline submission should include those with early clinical data (Phase 1 and 2) on any CNS compound for which Phase 3 data has not been presented. The goal is to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms since such data would also be of great interest. View submission instructions for a Pharmaceutical Pipeline Presentation.